Opinion|Videos|October 24, 2024
Osimertinib: Evolution of Treatment from Refractory Disease to Prevention of Drivers of Disease Progression
Author(s)Hatim Husain, MD
Panelist discusses how agents such as osimertinib, initially developed to target resistance mechanisms in refractory disease, are now being used proactively to prevent drivers of disease progression.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Agents such as osimertinib that first targeted resistance mechanisms in refractory disease are now being used to prevent drivers of disease progression.
- Please discuss your thoughts about this strategy.
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Theodore Wagener, PhD, of Ohio State discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.
Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.
Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR exon 20 insertion–mutant NSCLC.
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Advertisement
Advertisement